주식/증권
➡️ 중립
Is This the Right Time to Retain ILMN Stock in Your Portfolio?
요약
Illumina advances its sequencing strategy with strong NovaSeq X momentum and clinical demand, but China's weakness and macro pressures cloud the outlook.